NeuroPace upgraded to Buy with rising earnings estimates, suggesting potential stock price increase

From Nasdaq: 2024-12-25 12:00:10

NeuroPace, Inc. (NPCE) has received a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This reflects positivity about its earnings outlook, potentially leading to increased stock prices. The Zacks rating system tracks EPS estimates, showing the correlation between earnings revisions and stock movement.

Institutional investors factor in earnings estimates for stock valuation, influencing price movements. NeuroPace’s rising earnings estimates suggest an improved business outlook, prompting investors to push the stock higher. The Zacks Rank system, with a proven track record since 1988, uses earnings estimate revisions to classify stocks for potential investment decisions.

NeuroPace is expected to earn -$1 per share for fiscal year 2024, with a 21.3% year-over-year change. Analysts have raised estimates by 7.9% in the past three months. The Zacks system, unlike Wall Street analysts, maintains a balance of ‘buy’ and ‘sell’ ratings, positioning top stocks for market-beating returns based on superior earnings estimate revisions.

The Zacks Rank #2 upgrade places NeuroPace in the top 20% of Zacks-covered stocks for estimate revisions, indicating a potential move higher in the near term. Zacks is set to release its Top 10 Stocks for 2025, with historical performance showing significant gains. Interested individuals can access early tips on these stocks for 2025.



Read more at Nasdaq: NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?